针对阿波脂蛋白 (a) 的反感性寡核酸:两个随机,双盲,安慰剂对照,剂量范围的试验
Nicholas J Viney1, Julian C van Capelleveen2, Richard S Geary1
1Ionis Pharmaceuticals, Carlsbad, CA, USA.
Lancet (London, England)
|September 26, 2016
概括
在临床试验中,IONIS-APO (a) Rx和IONIS-APO (a) -LRx两种新型反感性寡核酸可显著降低高脂蛋白 (a) (Lp (a)). 这些疗法有望缓解与高Lp (a) 相关的心血管疾病风险.
科学领域:
- 心血管医学
- 药理学
- 遗传学
背景情况:
- 升高的脂蛋白 (Lp[a]) 是心血管疾病和动脉狭窄的流行遗传风险因素.
- 大约20%的人群有升高的Lp (a),但没有批准的特殊疗法来降低它.
- 反感性寡核酸提供了针对Lp (a) 度的潜在治疗策略.
研究的目的:
- 评估IONIS-APO(a) Rx和IONIS-APO(a) -LRx两种新型抗意义寡核酸的疗效,安全性和耐受性.
- 评估与剂量相关的Lp (a) 水平的降低.
- 确定这些疗法在减轻Lp (a) 中介心血管风险方面的潜力.
主要方法:
- 进行了两项随机,双盲,安慰剂控制的试验.
- 使用升级式皮下剂量对参与者进行IONIS- APO (a) Rx评估.
- 在健康志愿者中评估IONIS- APO (a) - LRx,使用单次和多次上升的皮下剂量.
主要成果:
- 在两个群体中,IONIS- APO (a) Rx显著降低了66. 8%和71. 6%的Lp (a) 值 (p< 0. 0001).
- 在40毫克组中,IONIS- APO (a) - LRx显示了剂量依赖的Lp (a) 降低,高达92% (p=0.0007).
- 这两种寡核酸被发现是安全的和可以容忍的,与治疗相关的不良反应最小.
结论:
- IONIS-APO (a) -LRx是一种新的,耐受且有效的治疗方法,用于降低Lp (a) 度.
- 这些反感性寡核酸可以减轻与升高的Lp (a) 相关的心血管风险.
- 对于患有心血管疾病或动脉狭窄症和Lp (a) 升高的患者,需要进一步发展.
相关概念视频
Pharmacogenomics: Identification of New Drug Targets
73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management
558
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
558
Experimental RNAi
8.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
63
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
siRNA - Small Interfering RNAs
18.9K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.9K


